Purification specialist BIA Separations to become part of Sartorius
Combination of businesses will create a premium portfolio for advanced therapies. BIA Separations will be Sartorius’ center of excellence for purification of cell and gene therapeutics.
The life science company Sartorius announced today it has entered into a definitive agreement to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. The transaction, which is subject to customary regulatory conditions, is expected to close in late 2020, and therefore will have no material impact on Sartorius’ 2020 results.
BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA’s technology for manufacturing scale purification is already used in production of the first commercialized advanced therapeutics and the company also has a strong presence with such novel drug candidates in the clinical pipeline. “Combining the teams and technologies of Sartorius and BIA will create a premium offering for the manufacturing of advanced therapies. The goal of our partnership is to enable such therapeutics to reach more patients faster and we are committed to continue delivering relevant innovations across the entire production chain,” commented Joachim Kreuzburg, CEO of Sartorius.